20
Participants
Start Date
February 14, 2023
Primary Completion Date
January 1, 2026
Study Completion Date
July 1, 2026
Denosumab
Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
Zoledronic Acid
Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Denosumab Placebo
Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
Zoledronic Acid Placebo
Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
University of Pittsburgh, Pittsburgh
The Claude D. Pepper Older Americans Independence Centers
OTHER
National Institute on Aging (NIA)
NIH
Nami Safai Haeri
OTHER